QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 protara-therapeutics-q3-eps-031-beats-038-estimate

Protara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of ...

 protara-therapeutics-q2-eps-035-beats-041-estimate

Protara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of ...

 jones-trading-initiates-coverage-on-protara-therapeutics-with-buy-rating-announces-price-target-of-21

Jones Trading analyst Soumit Roy initiates coverage on Protara Therapeutics (NASDAQ:TARA) with a Buy rating and announces Pr...

 protara-therapeutics-q1-eps-029-beats-045-estimate

Protara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of ...

 hc-wainwright--co-reiterates-buy-on-protara-therapeutics-maintains-23-price-target

HC Wainwright & Co. analyst Andres Maldonado reiterates Protara Therapeutics (NASDAQ:TARA) with a Buy and maintains $23 ...

 reported-saturday-protara-therapeutics-shares-interim-results-highlighting-durable-clinical-responses-with-tara-002-in-high-risk-nmibc

TARA-002 demonstrates 100% complete response rate at any time and 67% 12-month landmark complete response rate in BCG-Unrespons...

 protara-therapeutics-announces-conference-call-and-webcast-to-review-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-patients-with-nmibc-on-monday-april-28-2025

NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing tran...

 scotiabank-initiates-coverage-on-protara-therapeutics-with-sector-outperform-rating-announces-price-target-of-12

Scotiabank analyst George Farmer initiates coverage on Protara Therapeutics (NASDAQ:TARA) with a Sector Outperform rating an...

 cantor-fitzgerald-initiates-coverage-on-protara-therapeutics-with-overweight-rating

Cantor Fitzgerald analyst Li Watsek initiates coverage on Protara Therapeutics (NASDAQ:TARA) with a Overweight rating.

 lifesci-capital-initiates-coverage-on-protara-therapeutics-with-outperform-rating-announces-price-target-of-22

LifeSci Capital initiates coverage on Protara Therapeutics (NASDAQ:TARA) with a Outperform rating and announces Price Target ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION